STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
Novo Nordisk has stopped two trials of a drug that aims to tame inflammation as a way to improve cardiovascular health,…
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 302 articles · page 1 of 9 · fetched 27 minutes ago
STAT+: Not so fast: Diabetes association panel not done reviewing ejections from its June meeting
The American Diabetes Association “continues to move from crisis to crisis to crisis,” says one of five members ejected…
Read at source →
Opinion: What STAT readers think about M.D. vs. D.O., AI in medicine, surrogacy, and more
“A click, signature, or brief review should not magically transfer responsibility from an AI developer or platform to a…
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to…
Read at source →
STAT+: Top Boston hospitals clash over Medicare Advantage network after split
First, Mass General Brigham split with Dana-Farber. Now its Medicare Advantage plan is dropping the cancer hospital.
Read at source →
STAT+: After failure of Angelman syndrome drug, experts see hope in other experimental therapies
After the failure of an experimental drug for Angelman syndrome, experts cautioned that there is still reason to think…
Read at source →
STAT+: FDA takes another look at botanical drugs
The biggest barrier for a top schzophrenia treatment, Ionis' first approval for Alexander disease, and more biotech news
Read at source →
Disabled workers at greater risk of losing health insurance
An organ transplant first, new details on ADA conference controversy, and more health news from Morning Rounds
Read at source →
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
The latest pharma news from the Pharmalot campus brought to you by the Pharmalittle newsletter
Read at source →
Opinion: Make infectious disease data boring again
“Is CDC now applying different standards to state data depending on who governs the state or what political party won…
Read at source →
STAT+: Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say
In the months before killing her children, Lindsay Clancy repeatedly sought help for her deteriorating mental health.
Read at source →
Opinion: The FDA removed the red tape around one of the best drugs for children with schizophrenia. But the fear remains
Clozapine “is one of the most underused drugs in all of medicine,” writes Nitin Gogtay.
Read at source →
STAT+: Recipients of gene-edited pig kidneys successfully receive human organs
Two recipients of gene-edited pig kidneys have successfully received human organs, a milestone in the wider effort to…
Read at source →
STAT+: Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder
Zanvastro is the first disease-modifying treatment for Alexander disease, a rare and fatal disorder.
Read at source →
‘Tactical athletes’ get new guidance for cardiovascular fitness
Tactical athletes, a category of people first recognized in the early 2000s, also need distinct kinds of health care.
Read at source →
STAT+: Seattle scientists launch $95 million AI biology effort
Ultragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other biotech news
Read at source →
STAT+: Fauci speaks, and writes
Anthony Fauci is working on a book, we unpack Trump's latest drug pricing deals, and more from STAT's D.C. Diagnosis…
Read at source →
HHS flip-flops on disability lawsuit
Drug overdose deaths decreasing, a path to patients for AI devices, and more health news from Morning Rounds
Read at source →
STAT+: OpenEvidence launches new family of AI models
In this edition of STAT Health Tech: What FDA's TEMPO pilot means for AI regulation, OpenEvidence launches new AI…
Read at source →STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
The latest pharma news from the Pharmalot campus via the Pharmalittle newsletter
Read at source →
STAT+: Abivax has still not been acquired. What’s going on?
Biotech M&A activity is off the charts, yet the French drugmaker Abivax hasn't been picked up yet. There may be some…
Read at source →
STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized
AI products from Cadence and Limbic are among four devices recently accepted into the FDA’s TEMPO pilot that will allow…
Read at source →
Opinion: STAT+: A surprising bright spot at the FDA on regulating unproven stem cells
“These successes are surprising, worth discussing, and even celebrating a bit,” STAT Lab Dish columnist Paul Knoepfler…
Read at source →
Opinion: I was a doula before I was an OB-GYN. I wish the two professions understood each other more
“The longer I practice, the more I think many conflicts in maternity care come from a simple misunderstanding,” writes…
Read at source →
The pediatricians who take in vaccine-skeptical parents others won’t
At a "practice of last resort," pediatricians prioritize allaying parents' vaccine concerns without hardline dismissals.
Read at source →
Why are drug overdose deaths declining?
Naloxone and harm reduction measures may be helping to curb drug overdose deaths, a new report says.
Read at source →
STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham…
Read at source →
Doctors groups release vaccination guidelines ahead of respiratory illness season
Ahead of respiratory illness season, professional organizations have issued guidance on flu, Covid, and RSV vaccines.
Read at source →
STAT+: ARPA-H funds biotechs working on custom RNA therapies
Roche licenses a tri-specific antibody, new Trump deals may undercut its own goals, and other biotech news
Read at source →
STAT+: How a former ARPA-H director’s startup is tackling AI’s ‘dumb problems’
In this edition of STAT's AI Prognosis: A startup tackling the 'dumb problems' at the intersection of AI and bio,…
Read at source →
STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and…
Read at source →
HHS spins a tale of a would-be content creator child
The next DSM and the algorithm, an unexpected discovery on alpha-gal syndrome, and more health news from Morning Rounds
Read at source →
STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs
Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for…
Read at source →
STAT+: The Ig Nobel Prizes, long held in the U.S., head to Europe due to Trump policies
For the first time since they began, the Ig Nobel Prizes, a satirical version of the Nobel prizes, is being held…
Read at source →
Opinion: The next DSM should address the algorithm’s role in eating disorders
The new DSM, expected in 2030, should address the digital environments of eating disorders patients, experts write.
Read at source →
STAT+: ADA review of members’ expulsion denies group censored opinions, called in police
A review of findings from a five-person committee is being sent to the ADA board for action, STAT has learned, but it…
Read at source →